Oramed Pharmaceuticals Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports the final voting results from the 2022 Annual Meeting of Stockholders held by Oramed Pharmaceuticals Inc. on June 30, 2022. The company is incorporated in Delaware and trades on the Nasdaq Capital Market and Tel Aviv Stock Exchange under the symbol ORMP.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting outcomes.
Material Changes and Voting Results
Stockholders voted on four proposals. The results were as follows:
- Proposal 1 (Re-election of Directors): All five nominees (Dr. Miriam Kidron, Nadav Kidron, Dr. Arie Mayer, Yadin Rozov, and Leonard Sank) were re-elected. Significant broker non-votes (9,294,164) were recorded for all director candidates.
- Proposal 2 (Say-on-Pay): Stockholders approved the non-binding advisory vote on executive compensation with 10,073,933 votes for and 1,100,188 against.
- Proposal 3 (Stock Incentive Plan Amendment): Stockholders approved an amendment to the 2019 Stock Incentive Plan. The vote was closer than other proposals, with 5,858,015 for and 4,096,378 against.
- Proposal 4 (Auditor Ratification): Stockholders ratified the appointment of Kesselman & Kesselman as the independent registered public accounting firm for the 2022 fiscal year with 20,282,526 votes for and 168,072 against.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investors to Verify
- Verify the specific terms of the amendment approved for the 2019 Stock Incentive Plan, given the significant number of votes cast against it.
- Confirm the total number of shares outstanding and the percentage of shares represented by the 9,294,164 broker non-votes to understand the impact on director election thresholds.
- Review the company's most recent 10-K or 10-Q for financial performance data, as this 8-K contains no financial metrics.